The info below appeared in Seeking Alpha about an hour ago:
Regen Biopharma, Inc. (RGBP) - OTCPK - Current
$0.170.0003(0.18%)
12:09 PM, 12/29 - Data Delayed 15 minutes
Regen Biopharma, Inc. stock chart
Today5d1m3m1y5y10y
52wk high:0.45
52wk low:0.08
EPS:N/A
PE (ttm):N/A
Div Rate:N/A
Yield:N/A
Market Cap:$19.37m
Volume:108,769
LATESTANALYSISBREAKING NEWSSTOCKTALK
All
Regen Bio on go to start early-stage study of HemaXellerate in aplastic anemia
In a regulatory filing, Regen Biopharma (OTCPK:RGBP) reports that it was informed by the FDA that it has satisfied all clinical hold issues related to its IND for HemaXellerate and it is cleared to initiate a Phase 1 trial in patients with drug-refractory aplastic anemia.HemaXellerate is a personalized cellular therapeutic that is designed to stimulate blood production in patients whose bone marrow is not working properly.
| Tue, Dec. 15, 8:24 AM | 5 Comments
Regen Bio's dCellVax IND on go
The FDA issues IND No. 16200 to Regen BioPharma (OTCPK:RGBP -1.9%) for a proposed Phase 1/2 clinical trial to evaluate dCellVax for the treatment for breast cancer. The one-year study will recruit 10 patients with metastatic breast cancer. Each will receive four monthly injections of the dCellVax gene silenced dendritic cell therapy. Patients will be assessed at six and twelve months.
| Nov. 4, 2014, 12:47 PM | 14 Comments
Regen Bio submits IND for breast cancer therapy candidate
Regen BioPharma (OTCPK:RGBP +13%) submits an IND to the FDA for clearance to begin a clinical trial to assess the safety and effectiveness of its immunotherapeutic product candidate, dCellVax, for the treatment of metastatic breast cancer.dCellVax's mode of action is silencing genes that suppress the body's immune response to cancer.
